Evidence map›Paper›PMID 23776620›Full record

ArticlePloS one2013

A novel strategy to increase the proliferative potential of adult human β-cells while maintaining their differentiated phenotype.

Haytham Aly, Nidhi Rohatgi, Connie A Marshall, Tiffani C Grossenheider, Hiroyuki Miyoshi, Thaddeus S Stappenbeck, Scot J Matkovich, Michael L McDaniel

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. CD47 and thrombospondin-1 regulation of mitochondria, metabolism, and diabetes.American journal of physiology. Cell physiology · 2021
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Erythropoietin and diabetes mellitus.World journal of diabetes · 2015
    Review
  19. Review
  20. Can we safely target the WNT pathway?Nature reviews. Drug discovery · 2014
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Haytham AlyDepartment of Pathology and Immunology Washington University in St. Louis, St. Louis, Missouri, United States of America.
Nidhi Rohatgi
Connie A Marshall
Tiffani C Grossenheider
Hiroyuki Miyoshi
Thaddeus S Stappenbeck
Scot J Matkovich
Michael L McDaniel
Washington University in St. Louis · US

Funding

WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Jennifer Lynn Powers Carson · 2013 to 2026
$27.1M
TRANSGENICS COREP60DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI SCHAFFER, JEAN E. · 1986 to 2012
$25.2M
STUDY OF SECRETION AND BIOSYNTHESIS OF INSULINR01DK006181 · NIDDK · WASHINGTON UNIVERSITY · PI MCDANIEL, MICHAEL L. · 1986 to 2012
$4.1M
CELL BIOLOGIC APPROACHES TO DIABETES RESEARCHT32DK007296 · NIDDK · WASHINGTON UNIVERSITY · PI COLONNA, MARCO · 1986 to 2014
$3.3M
RESPONSES OF INTESTINAL STEM CELLS TO EPITHELIAL INJURYR01DK071619 · NIDDK · WASHINGTON UNIVERSITY · PI STAPPENBECK, THADDEUS S · 2008 to 2017
$3.2M
Secretion and Biosynthesis of InsulinR56DK006181 · NIDDK · WASHINGTON UNIVERSITY · PI MCDANIEL, MICHAEL L. · 2007 to 2007
$249k
NIDDK NIH HHS DK006181NIDDK NIH HHS DK00618146S1NIDDK NIH HHS DK07296NIDDK NIH HHS DK20579NIDDK NIH HHS P30 DK020579NIDDK NIH HHS P60 DK020579NIDDK NIH HHS R01 DK006181NIDDK NIH HHS R01 DK071619NIDDK NIH HHS R56 DK006181NIDDK NIH HHS T32 DK007296
6 · The paper itself

Abstract

Our previous studies demonstrated that Wnt/GSK-3/β-catenin and mTOR signaling are necessary to stimulate proliferative processes in adult human β-cells. Direct inhibition of GSK-3, that engages Wnt signaling downstream of the Wnt receptor, increases β-catenin nuclear translocation and β-cell proliferation but results in lower insulin content. Our current goal was to engage canonical and non-canonical Wnt signaling at the receptor level to significantly increase human β-cell proliferation while maintaining a β-cell phenotype in intact islets. We adopted a system that utilized conditioned medium from L cells that expressed Wnt3a, R-spondin-3 and Noggin (L-WRN conditioned medium). In addition we used a ROCK inhibitor (Y-27632) and SB-431542 (that results in RhoA inhibition) in these cultures. Treatment of intact human islets with L-WRN conditioned medium plus inhibitors significantly increased DNA synthesis ∼6 fold in a rapamycin-sensitive manner. Moreover, this treatment strikingly increased human β-cell proliferation ∼20 fold above glucose alone. Only the combination of L-WRN conditioned medium with RhoA/ROCK inhibitors resulted in substantial proliferation. Transcriptome-wide gene expression profiling demonstrated that L-WRN medium provoked robust changes in several signaling families, including enhanced β-catenin-mediated and β-cell-specific gene expression. This treatment also increased expression of Nr4a2 and Irs2 and resulted in phosphorylation of Akt. Importantly, glucose-stimulated insulin secretion and content were not downregulated by L-WRN medium treatment. Our data demonstrate that engaging Wnt signaling at the receptor level by this method leads to necessary crosstalk between multiple signaling pathways including activation of Akt, mTOR, Wnt/β-catenin, PKA/CREB, and inhibition of RhoA/ROCK that substantially increase human β-cell proliferation while maintaining the β-cell phenotype.

Indexed as

AdultAmidesBenzamidesbeta CateninCarrier ProteinsCell Culture TechniquesCell DifferentiationCell ProliferationCulture Media, ConditionedDioxolesGene Expression ProfilingHumansInsulin-Secreting CellsNoggin ProteinPyridinesReceptor Cross-Talk4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamideAmidesBenzamidesbeta CateninCarrier ProteinsCulture Media, ConditionedDioxolesNoggin ProteinPyridinesrho-Associated KinasesRSPO3 protein, humanR-SpondinsThrombospondinsWnt3A ProteinWNT3A protein, humanY 27632

Identifiers

PMID23776620
PMCPMC3680388
OpenAlexW2142109875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.